On Monday, Shares of Organovo Holdings Inc (NASDAQ:ONVO), subtract -1.20% and closed at $3.28 in the last trading session. The last trading range of the stock ranges between $3.23 and $3.40. Organovo Holdings, Inc. (ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, recently declared that Chairman and Chief Executive Officer Keith Murphy is planned to speak at the 2016 Canaccord Genuity Medical Technologies & Diagnostics Forum in New York on Thursday, November 17th at 1:00 p.m. Eastern Time (ET). The presentation will be simultaneously audio webcast. The audio webcast will be archived for 90 days following the conference.
Omeros Corporation (NASDAQ:OMER), jumped 6.40% and closed at $13.46 in the last trading session. The last trading range of the stock ranges between $12.52 and $13.47. The company’s Market capitalization is $612.79 million with the total Outstanding Shares of 42.92 million. Omeros Corporation (OMER) recently declared pharmacokinetic and pharmacodynamic data from the evaluation of OMS906 in non-human primates. OMS906 inhibits mannan-binding lectin-associated serine protease-3 (MASP-3), the protein critical to activation of the alternative pathway of complement (APC), a key component of the immune system. MASP-3 is responsible for the conversion of pro-factor D to factor D. Converted factor D is necessary for the activation of the APC. The APC is involved in a wide range of diseases, counting paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, age-related macular degeneration, arthritis, asthma and traumatic brain injury.
Single-dose administration of OMS906 to cynomolgus monkeys resulted in sustained ablation of systemic APC activity for about 16 days. The extent of APC ablation was comparable to that achieved by complete inhibition of factor D in vitro, indicating that OMS906 fully blocked the conversion of pro-factor D to factor D. Similar results were obtained with a number of the company’s other antibodies targeting MASP-3. No safety concerns were identified.